版本:
中国

BRIEF-Egalet announces results after study of ARYMO ER extended-release tablets

Sept 22 Egalet Corp

* Announces results from a category 3 oral human abuse potential study and a category 3 intranasal hap study of product candidate ARYMO ER extended-release tablets

* Announces publications in pain medicine from ARYMO ER oral and intranasal human abuse potential studies

* FDA Prescription Drug User Fee Act (PDUFA) goal date for a decision on ARYMO ER New Drug Application (NDA) is October 14, 2016.

* No serious adverse events were reported

* Manipulated ARYMO ER demonstrated a statistically significant reduction in maximum drug liking (Emax) compared to crushed MS Contin Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐